{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:35:10Z","timestamp":1783103710367,"version":"3.54.6"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/bor.0000000000000272","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T11:38:31Z","timestamp":1457005111000},"page":"251-258","source":"Crossref","is-referenced-by-count":59,"title":["Suppression of normal immune responses after treatment with rituximab"],"prefix":"10.1097","volume":"28","author":[{"given":"Ruba","family":"Kado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joseph","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rdc.2004.01.006","article-title":"B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.","volume":"30","author":"Edwards","year":"2004","journal-title":"Rheum Dis Clin N Am"},{"issue":"suppl 1","key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","article-title":"B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthr Res Ther"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2015.10.005","article-title":"Systemic sclerosis: new evidence re-enforces the role of B cells.","volume":"15","author":"Sakkas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis.","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","article-title":"A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections.","volume":"97","author":"Seyfizadeh","year":"2016","journal-title":"Cri Rev OncolHematol"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy.","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Direct Autoimmun"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkins lymphoma.","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.","volume":"58","author":"Dass","year":"2008","journal-title":"Arthr Rheum"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study.","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-014-2816-7","article-title":"Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.","volume":"34","author":"Chocova","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1136\/annrheumdis-2014-206496","article-title":"Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.","volume":"74","author":"Md Yusof","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature.","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK).","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthr Rheum"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.","volume":"58","author":"Roll","year":"2008","journal-title":"Arthr Rheum"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00277-014-2103-3","article-title":"Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.","volume":"93","author":"Witzens-Harig","year":"2014","journal-title":"Ann Hematol"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics.","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthr Rheum"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years.","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jbspin.2014.06.011","article-title":"Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.","volume":"81","author":"Sebastiani","year":"2014","journal-title":"Joint Bone Spine"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskel Disord"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multisystem autoimmune disease.","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12891-015-0860-3","article-title":"Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.","volume":"17","author":"Besada","year":"2016","journal-title":"BMC Musculoskel Disord"},{"key":"R31-9-20210128","first-page":"616787","article-title":"Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia.","volume":"2015","author":"Arroyo-Avila","year":"2015","journal-title":"Case Rep Rheumatol"},{"key":"R32-9-20210128","first-page":"345","article-title":"Early onset neutropenia after rituximab in lupus nephritis.","volume":"25","author":"Enriquez","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthr Rheum"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/qjmed\/hcs015","article-title":"Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.","volume":"105","author":"Besada","year":"2012","journal-title":"QJM"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.130526","article-title":"Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab.","volume":"41","author":"Abdulkader","year":"2014","journal-title":"J Rheumatol"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"e000034","DOI":"10.1136\/rmdopen-2014-000034","article-title":"Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.","volume":"1","author":"Salmon","year":"2015","journal-title":"RMD Open"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","article-title":"Neutropenia after rituximab treatment: new insights on a late complication.","volume":"19","author":"Wolach","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-6143.2003.00646.x","article-title":"Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.","volume":"5","author":"Bearden","year":"2005","journal-title":"Am J Transplant"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1128\/JVI.77.3.2165-2173.2003","article-title":"Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.","volume":"77","author":"Schmitz","year":"2003","journal-title":"J Virol"},{"key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness.","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthr Rheum"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":"B, Mahlaoui N, Ceredih, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency.","volume":"134","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.iac.2015.07.009","article-title":"Common variable immunodeficiency: diagnosis, management treatment.","volume":"35","author":"Abbott","year":"2015","journal-title":"Immunol Allergy Clin N Am"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/cei.12178","article-title":"New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.","volume":"174","author":"Ameratunga","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"R47-9-20210128","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jaci.2013.01.036","article-title":"Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement.","volume":"131","author":"Agarwal","year":"2013","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T13:14:52Z","timestamp":1654521292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201605000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000272","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}